

ATHEROGENICS INC  
Form 8-K  
January 09, 2007

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

---

FORM 8-K

---

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): **January 8, 2007**

**ATHEROGENICS, INC.**  
(Exact Name of Registrant as Specified in its Charter)

|                                                                        |                                               |                                                                    |
|------------------------------------------------------------------------|-----------------------------------------------|--------------------------------------------------------------------|
| <b>Georgia</b><br>(State or other<br>jurisdiction<br>of incorporation) | <b>0-31261</b><br>(Commission<br>File Number) | <b>58-2108232</b><br>(I.R.S. Employer<br>Identification<br>Number) |
|------------------------------------------------------------------------|-----------------------------------------------|--------------------------------------------------------------------|

**8995 Westside Parkway**  
**Alpharetta, GA 30004**  
(Address of principal executive offices)

Registrant's telephone number, including area code **(678) 336-2500**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01 Other Events.**

On January 8, 2007, AtheroGenics, Inc. issued a press release to provide an update on its Phase III clinical trial, ARISE, for the treatment of atherosclerosis in patients with coronary heart disease. A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits.**

The following exhibit is attached to this current report on Form 8-K as Exhibit 99.1.

| <u>Exhibit No.</u> | <u>Description</u>                     |
|--------------------|----------------------------------------|
| 99.1               | - Press Release dated January 8, 2007. |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

**ATHEROGENICS, INC.**

Date: January 9, 2007

/s/MARK P. COLONNESE

Mark P. Colonnese

Executive Vice President, Commercial  
Operations

and Chief Financial Officer

\_\_\_\_\_

**EXHIBIT INDEX**

| <u>Exhibit No.</u> | <u>Description</u>                    |
|--------------------|---------------------------------------|
| 99.1               | - Press Release dated January 8, 2007 |